Michael H. Davidson - Dec 10, 2024 Form 4 Insider Report for TENAX THERAPEUTICS, INC. (TENX)

Role
Director
Signature
/s/ S. Halle Vakani, as Attorney-in-Fact
Stock symbol
TENX
Transactions as of
Dec 10, 2024
Transactions value $
$0
Form type
4
Date filed
12/12/2024, 07:54 PM
Previous filing
Oct 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TENX Common Stock 2.88K Dec 10, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TENX Stock Option (right to buy) Award $0 +100K $0.00 100K Dec 10, 2024 Common Stock 100K $5.94 Direct
holding TENX Stock Option (right to buy) 4 Dec 10, 2024 Common Stock 4 $3,200.00 Direct
holding TENX Stock Option (right to buy) 4 Dec 10, 2024 Common Stock 4 $992.00 Direct
holding TENX Pre-Funded Warrant 47.5K Dec 10, 2024 Common Stock 47.5K $0.01 Direct F1
holding TENX Warrant 25K Dec 10, 2024 Common Stock 25K $4.50 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The pre-funded warrant has no expiration date.
F2 The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) ( NCT05983250 ) (the "Topline Data Announcement"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029.